

University of Groningen

Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis

Jansz, Thijs T.; van Reekum, Franka E.; Ozyilmaz, Akin; de Jong, Pim A.; Boereboom, Franciscus T. J.; Hoekstra, Tiny; Verhaar, Marianne C.; van Jaarsveld, Brigit C.

Published in:
 American Journal of Nephrology

DOI:
[10.1159/000494665](https://doi.org/10.1159/000494665)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Jansz, T. T., van Reekum, F. E., Ozyilmaz, A., de Jong, P. A., Boereboom, F. T. J., Hoekstra, T., ... van Jaarsveld, B. C. (2018). Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis. *American Journal of Nephrology*, 48(5), 369-377. <https://doi.org/10.1159/000494665>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis

Thijs.T Jansz^a Franka E. van Reekum^a Akin Özyilmaz^{b, c} Pim A. de Jong^d
Franciscus T.J. Boereboom^{e, f} Tiny Hoekstra^g Marianne C. Verhaar^a
Brigit C. van Jaarsveld^{e, g}

^aDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; ^bDivision of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands; ^cDialysis Center Groningen, Groningen, The Netherlands; ^dDepartment of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands; ^eDianet Dialysis Centers, Utrecht, The Netherlands; ^fDepartment of Internal Medicine, Diaconessenhuis Utrecht, Utrecht, The Netherlands; ^gDepartment of Nephrology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Keywords

Coronary artery calcification · Hemodialysis · Peritoneal dialysis

Abstract

Background: Vascular calcification is seen in most patients on dialysis and is strongly associated with cardiovascular mortality. Vascular calcification is promoted by phosphate, which generally reaches higher levels in hemodialysis than in peritoneal dialysis. However, whether vascular calcification develops less in peritoneal dialysis than in hemodialysis is currently unknown. Therefore, we compared coronary artery calcification (CAC), its progression, and calcification biomarkers between patients on hemodialysis and peritoneal dialysis. **Methods:** We measured CAC in 134 patients who had been treated exclusively with hemodialysis ($n = 94$) or peritoneal dialysis ($n = 40$) and were transplantation candidates. In 57 of them (34 on hemodialysis and 23 on peritoneal dialysis), we also measured CAC progression annually up to 3 years and the inactive species of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, osteo-

protegerin. We compared CAC cross-sectionally with Tobit regression. CAC progression was compared in 2 ways: with linear mixed models as the difference in square root transformed volume score per year (Δ CAC SQRV) and with Tobit mixed models. We adjusted for potential confounders. **Results:** In the cross-sectional cohort, CAC volume scores were 92 mm³ in hemodialysis and 492 mm³ in peritoneal dialysis (adjusted difference 436 mm³; 95% CI –47 to 919; $p = 0.08$). In the longitudinal cohort, peritoneal dialysis was associated with significantly more CAC progression defined as Δ CAC SQRV (adjusted difference 1.20; 95% CI 0.09 to 2.31; $p = 0.03$), but not with Tobit mixed models (adjusted difference in CAC score increase per year 106 mm³; 95% CI –140 to 352; $p = 0.40$). Peritoneal dialysis was associated with higher osteoprotegerin (adjusted $p = 0.02$) but not with dp-ucMGP or fetuin-A. **Conclusions:** Peritoneal dialysis is not associated with less CAC or CAC progression than hemodialysis, and perhaps with even more progression. This indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.

© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Cardiovascular disease is the leading cause of death among patients with end-stage renal disease [1, 2]. This high cardiovascular mortality is strongly associated with vascular calcification [3, 4], which occurs frequently [2] and progresses almost universally in end-stage renal disease [5]. Vascular calcification can be measured at various sites, such as the coronary arteries, and is promoted by phosphate, which is frequently elevated in end-stage renal disease [6, 7].

Remarkably, it is unknown whether vascular calcification is affected by dialysis modality, of which the 2 major types are hemodialysis and peritoneal dialysis. In theory, peritoneal dialysis might induce less vascular calcification than hemodialysis because patients on peritoneal dialysis generally have lower serum phosphate [8] probably owing to their continuous clearance. However, there have never been randomized studies on this subject, as randomization to dialysis modality is generally refused by patients [9]. Moreover, patients on peritoneal dialysis are typically younger and healthier due to the prerequisites of treatment at home [10], which has hampered previous observational research that did not attempt to statistically adjust for this [11–14].

To overcome this, we compared patients treated with hemodialysis or peritoneal dialysis who were all eligible for transplantation and thus relatively comparable in age and comorbidities. First, we compared coronary artery calcification (CAC) cross-sectionally between prevalent patients who had been treated exclusively with hemodialysis or peritoneal dialysis. Second, we compared CAC progression up to 3 years among those who underwent follow-up measurements. Additionally, we studied calcification biomarkers in relation to CAC progression, and compared these between patients on hemodialysis and peritoneal dialysis.

Methods

Cross-Sectional Cohort

We analyzed a cross-sectional sample of patients that had been treated exclusively with conventional hemodialysis or peritoneal dialysis and participated in the NOCTx study. NOCTx (NCT00950573) is a prospective nonrandomized study that included patients on chronic conventional hemodialysis or peritoneal dialysis with a minimum dialysis vintage of 2 months, patients who switched to nocturnal hemodialysis, and patients who received a kidney transplant. Thus, all patients had been treated with hemodialysis or peritoneal dialysis at inclusion. Patients were eligible when aged between 18 and 75 years and were candidates for

transplantation when on dialysis. NOCTx excluded patients with a life expectancy <3 months, non-adherence to dialysis regimens, drug abuse, and pregnancy.

Between December 2009 and February 2016, 329 patients were screened for eligibility in 8 Dutch dialysis centers. NOCTx included 181 of these patients, of whom 135 were being treated with hemodialysis and 46 with peritoneal dialysis at inclusion. We excluded patients who were treated with hemodialysis >16 h per week ($n = 14$), as we theorized that more intensive dialysis regimens might mitigate calcification. Furthermore, we excluded patients who had a history of treatment with the other modality of over 3 months ($n = 33$), leaving a sample of 134 patients.

Longitudinal Cohort

We analyzed a longitudinal sample of patients from the NOCTx study who continued treatment with conventional hemodialysis or peritoneal dialysis after inclusion and completed at least one follow-up visit ($n = 57$). In NOCTx, CAC was measured at inclusion, and after 1, 2 and 3 years. Also, blood was collected in 4.5 mL potassium-ethylenediaminetetraacetic acid vacutainers (on a non-dialysis day in case of hemodialysis), immediately centrifuged and stored in aliquots at -80°C without thawing at inclusion. Patients left the study if their renal replacement therapy was changed.

Treatment Characteristics

Patients were treated according to the Kidney Disease: Improving Global Outcomes guidelines by the attending nephrologists [15]. Hemodialysis was delivered 3 times a week for 4 h with a default 1.50 mmol/L dialysate calcium concentration, and peritoneal dialysis as automatic or continuous ambulant peritoneal dialysis with a default 1.25 mmol/L dialysate calcium concentration.

CAC Measurements

We determined CAC scores on nonenhanced, prospectively triggered cardiac multi-slice computed tomography (iCT 256, Philips Healthcare, Best, The Netherlands). Acquisition parameters were as follows: 120 kV, 40–50 mAs, rotation time 270 ms, and 128×0.625 mm collimation. Metoprolol was administered intravenously if heart rate was above 60/min to improve imaging quality. We used a calcium threshold of ≥ 130 Hounsfield units. A single observer (T.T.J.) read all scans chronologically per patient in order to exclude segments with severe motion artefacts or stents at a given scan from an entire set. Using commercially available software (Heartbeat CS, Philips Healthcare, The Netherlands), we calculated calcium volume scores. Reproducibility of CAC measurements has been shown to be excellent, with an intraclass correlation coefficient of >0.95 [16].

Calcification Biomarker Measurements

Plasma levels of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) were determined as described before [17]. The within-run and total variations of this assay were 0.8–6.2% and 3.0–8.2%, respectively. The assay measuring range was between 300 and 12,000 pmol/L and was linear up to 11,651 pmol/L [18]. The dp-ucMGP assays were performed in a single run by the laboratory of Coagulation Profile, department of Biochemistry, Maastricht, The Netherlands. Plasma fetuin-A and osteoprotegerin levels were measured with a Bio-Plex system (Bio-Rad) multiplex assay by the laboratory of the University Medical Center Utrecht, Utrecht, The Netherlands. All assays were executed in a single run.

Other Study Variables

Study personnel recorded demographic and clinical parameters at inclusion (pre-dialysis blood pressure and post-dialysis weight averaged from routine measurements during 3 hemodialysis sessions or 2 outpatient visits in case of peritoneal dialysis). Laboratory parameters (total calcium, albumin, phosphate, C-reactive protein, and parathyroid hormone) were obtained at inclusion by averaging routine measurements from 3 months, performed with standard laboratory techniques at the local treatment facilities. We classified residual urine production as present (≥ 100 mL/24 h) or absent. We defined dialysis vintage as the time between the first day of dialysis and the day of scanning, minus the time with a functioning kidney transplant.

Statistical Analyses

We reported normally distributed variables as mean \pm SD, non-normally distributed variables as median (interquartile range [IQR]), and categorical data as number (percentage). We compared normally distributed variables with Student *t* tests, non-normally distributed variables with Mann-Whitney-U tests, and categorical data with chi-square tests.

We compared CAC volume scores cross-sectionally with Tobit regression. Tobit regression can be used to analyze variables with floor and/or ceiling effects [19]. This may be the case with CAC scores, when calcification can be present below the detection limit while the CAC score is 0. With Tobit regression, we assume our outcome variable is actually a normally distributed variable that has been truncated (here CAC score truncated at zero). By modeling this latent underlying variable, values of zero do not need to be excluded from the analyses and do not severely skew the results [19, 20].

To compare CAC progression, we used 2 different approaches, since a valid standard method to analyze CAC progression is lacking. First, we analyzed CAC progression with linear mixed models as change per year in square root transformed volume scores (Δ CAC SQRV). This approach, also known as Hokanson's method, accounts for interscan variability [21] and has been used by others [22]. We adjusted these analyses for CAC SQRV at inclusion. Second, we used Tobit mixed models to analyze CAC progression. We adjusted for factors known to induce calcification [23]: age (years), sex (male/female), presence of diabetes mellitus (yes/no), dialysis vintage (months), presence of residual urine production ≥ 100 mL/24 h (yes/no), and vitamin K antagonist use (yes/no).

We used linear regression to compare biomarker levels between dialysis modalities. Dp-ucMGP levels were log-transformed, as these were right-skewed. We adjusted for potential confounders as described above. To determine the relationship between biomarkers and Δ CAC SQRV between inclusion and 1 year, we calculated Pearson's correlation coefficients.

We report regression coefficients with 95% CI. We considered *p* values ≤ 0.05 (2-tailed) statistically significant and used R 3.4.1 (R Foundation Statistical Computing) for all analyses.

Results

Cross-Sectional Cohort

The cross-sectional cohort included 134 patients who had been treated exclusively with hemodialysis (*n* = 94)

or peritoneal dialysis (*n* = 40). The mean age of this cohort was 54 ± 12 years, 94 (70%) were male, median dialysis vintage was 17 (IQR 10–34) months, and 24 (18%) had diabetes mellitus. The patients on hemodialysis had a median 6-month longer dialysis vintage, were somewhat heavier, had higher blood pressures, and had lower calcium and higher albumin levels than the patients on peritoneal dialysis (Table 1). Phosphate levels were not significantly higher in the patients on hemodialysis.

CAC volume scores were 92 (IQR 1–663) in the patients on hemodialysis and 492 (IQR 92–1,139) in the patients on peritoneal dialysis. The distribution of the CAC volume scores is illustrated by a smoothed version of a histogram (Kernel density plot) in online supplementary Figure S1 (for all online suppl. material, see www.karger.com/doi/10.1159/000494665). In Tobit regression, the CAC volume scores were not significantly (*p* = 0.15) higher in patients on peritoneal dialysis compared to patients on hemodialysis (difference 342 mm^3 ; 95% CI -125 to 808). When adjusted for age, sex, diabetes mellitus, dialysis vintage, residual urine production, and vitamin K antagonist use, peritoneal dialysis was also not significantly (*p* = 0.08) associated with more CAC than hemodialysis (difference 436 mm^3 ; 95% CI -47 to 919).

Longitudinal Cohort

The longitudinal cohort included 57 patients treated with hemodialysis (*n* = 34) or peritoneal dialysis (*n* = 23) who completed at least one follow-up visit. The mean age of this cohort was 52 ± 13 years, 37 (65%) were male, median dialysis vintage was 17 (IQR 8–47) months, and 7 (12%) had diabetes mellitus. The patients on hemodialysis were somewhat heavier, had higher systolic blood pressures, tended to have longer dialysis vintages, tended to use more vitamin K antagonists, and had lower calcium and higher albumin levels than the patients on peritoneal dialysis (Table 1), whereas their other characteristics were comparable. Notably, CAC volume scores at inclusion were not significantly different between patients on hemodialysis (median 163, IQR 5–745) and patients on peritoneal dialysis (median 76, IQR 2–696, *p* = 0.68), nor was the proportion of patients with zero calcification (*n* = 8, 24% vs. *n* = 6, 26%, respectively, *p* = 0.99). There were also no significant differences between the longitudinal cohort (*n* = 57) and those who underwent treatment with hemodialysis or peritoneal dialysis after inclusion but did not undergo follow-up CAC measurements (online suppl. Table S1).

The maximum follow-up duration was 1 year for 25 patients, 2 years for 18 patients, and 3 years for 14 patients.

Table 1. Characteristics of the 134 patients included in the cross-sectional CAC analysis and of the 57 patients included in the CAC progression analyses, stratified by dialysis modality

	Cross-sectional cohort		<i>p</i> for difference	Longitudinal cohort		<i>p</i> for difference
	hemodialysis (<i>n</i> = 94)	peritoneal dialysis (<i>n</i> = 40)		hemodialysis (<i>n</i> = 34)	peritoneal dialysis (<i>n</i> = 23)	
<i>Demographics and medical history</i>						
Age, years	56±11	51±15	0.06	54±12	49±14	0.17
Male, <i>n</i> (%)	62 (66)	32 (80)	0.16	20 (59)	17 (74)	0.37
Body mass index, kg/m ²	26.2±4.4	24.7±3.3	0.05	26.7±4.9	24.5±3.4	0.04
Systolic blood pressure, mm Hg	143±20	135±13	0.03	142±20	132±18	0.05
Diastolic blood pressure, mm Hg	79±12	85±10	<0.01	79±11	82±14	0.29
Diabetes mellitus, <i>n</i> (%)	21 (22)	3 (8)	0.07	6 (18)	1 (4)	0.28
Cardiovascular disease, <i>n</i> (%)	23 (25)	10 (25)	0.99	7 (21)	5 (22)	0.99
Current smoker, <i>n</i> (%)	13 (14)	5 (13)	0.99	4 (12)	1 (4)	0.62
<i>History of kidney disease</i>						
Dialysis vintage, months	19 (11–35)	13 (7–31)	0.05	26 (10–56)	12 (5–47)	0.06
Cause of end-stage renal disease, <i>n</i> (%)			0.42			0.49
Cystic kidney disease	18 (19)	6 (15)		4 (12)	5 (22)	
Interstitial nephritis	5 (5)	1 (3)		2 (6)	1 (4)	
Glomerulonephritis	24 (26)	7 (18)		9 (26)	5 (22)	
Vascular disease	21 (22)	11 (28)		8 (24)	5 (22)	
Diabetic nephropathy	10 (11)	2 (5)		5 (15)	1 (4)	
Other	8 (9)	7 (18)		4 (12)	6 (26)	
Unknown	8 (9)	6 (15)		2 (6)	0	
<i>Dialysis therapy and kidney function</i>						
Dialysis therapy						
Weekly hemodialysis sessions	3.1±0.5	–		2.9±0.3	–	
Weekly hemodialysis hours	11.4±2.0	–		11.0±2.0	–	
Daily peritoneal dialysis dwells	–	4.4±0.6		–	4.3±0.6	
Daily peritoneal dialysis volume, L	–	9.8±2.4		–	9.0±2.2	
Kidney function						
Residual urine production ≥100 mL/24 h <i>n</i> (%)	55 (59)	29 (73)	0.18	20 (59)	14 (61)	0.99
<i>Medication use*</i>						
Vitamin K antagonist, <i>n</i> (%)	12 (15)	1 (3)	0.11	7 (21)	0	0.06
Vitamin D analogue, <i>n</i> (%)	61 (75)	32 (89)	0.15	29 (85)	19 (83)	0.99
Calcium-containing phosphate binder, <i>n</i> (%)	28 (35)	14 (39)	0.81	18 (53)	10 (44)	0.67
Cinacalcet, <i>n</i> (%)	16 (20)	7 (19)	0.99	8 (24)	3 (13)	0.52
<i>Laboratory parameters</i>						
Calcium, mmol/L	2.3±0.1	2.4±0.1	0.01	2.3±0.1	2.4±0.1	0.01
Albumin, g/L	41.4±3.2	38.3±3.6	<0.001	40.8±3.0	38.5±3.5	0.02
Phosphate, mmol/L	1.6±0.4	1.6±0.4	0.69	1.6±0.3	1.6±0.3	0.50
C-reactive protein, mg/L	3 (2–6)	3 (1–13)	0.93	2 (2–7)	2 (1–18)	0.91
Parathyroid hormone, pmol/L	22 (15–41)	22 (14–37)	0.53	30 (17–48)	22 (15–41)	0.53

Data are presented as mean ± SD, median (IQR) or number (%).

* In the cross-sectional cohort, data on medication use were available in 81 patients on hemodialysis and 36 patients on peritoneal dialysis; in the longitudinal cohort data on medication use were available in all patients.

CAC, coronary artery calcification.

CAC progressed in most patients, but only in 2 of 8 patients on hemodialysis without CAC at inclusion, and in 2 of 6 patients on peritoneal dialysis without CAC at inclusion (Fig. 1). We analyzed CAC progression as ΔCAC SQRV with linear mixed models and with Tobit mixed models.

CAC progressed with 1.72 ΔCAC SQRV per year in patients on hemodialysis (95% CI 0.81 to 2.64) and with 2.73 ΔCAC SQRV per year in patients on peritoneal dialysis (95% CI 1.58 to 3.88; Fig. 2). As can be seen in Table 2, peritoneal dialysis was not significantly (*p* = 0.18) as-

Fig. 1. CAC progression in 57 patients on dialysis stratified by dialysis modality, depicted as individual trajectories of calcium volume scores. Individual trajectories of change in calcium volume score in patients on hemodialysis (left panel) and patients on peritoneal dialysis (right panel). Trajectories of 2 patients on hemodialysis and one on peritoneal dialysis with scores > 5,000 are not shown in this figure. Number of patients shown at 0, 1, 2, and 3 years: hemodialysis 32, 32, 21, and 10; peritoneal dialysis: 22, 22, 7, and 4. Note that lines may overlap around 0.




Fig. 2. CAC progression per year in 57 patients on dialysis stratified by dialysis modality, depicted as boxplots of change in square root transformed volume score. Change in square root transformed volume scores (Y-axis) stratified by dialysis modality (X-axis) as boxplots. Note that square root transformations cannot be back-transformed. Number of patients per group per period (N) denoted below the boxplots. Crude P for difference in change in square root transformed volume score per year: 0.18; adjusted P for difference in change in square root transformed volume score per year: 0.03.




Table 2. Effect estimates of CAC progression for peritoneal dialysis ($n = 23$) compared to hemodialysis ($n = 34$) analyzed with linear mixed models as Δ CAC SQRV and with Tobit mixed models, with different multivariate adjustments

	Unadjusted	CAC SQRV at inclusion*	Adjustment for age and gender†	Full adjustment‡
Δ CAC SQRV	1.01 (-0.47 to 2.47)	1.22 (0.16 to 2.29)	1.25 (0.19 to 2.33)	1.20 (0.09 to 2.31)
Tobit regression	189 (-81 to 459)	-	77 (-184 to 338)	106 (-140 to 352)

*Tobit mixed models could not be adjusted for CAC SQRV at inclusion.

†The linear mixed models of Δ CAC SQRV were additionally adjusted for CAC SQRV at inclusion.

‡Full adjustment included age, sex, diabetes mellitus, dialysis vintage, presence of residual urine production, and vitamin K antagonist use. The linear mixed models of Δ CAC SQRV were additionally adjusted for CAC SQRV at inclusion

95% CI between brackets.

CAC, coronary artery calcification.

sociated with higher Δ CAC SQRV than hemodialysis in unadjusted analyses (difference in Δ CAC SQRV per year 1.01; 95% CI -0.47 to 2.47). When adjusted for CAC SQRV at inclusion, age, sex, diabetes mellitus, dialysis vintage, vitamin K antagonist use, and presence of residual urine production, peritoneal dialysis was significantly ($p = 0.03$) associated with 1.20 Δ CAC SQRV per year higher CAC progression compared to hemodialysis (95% CI 0.09–2.31).

In Tobit mixed models, CAC progressed with 99 mm³ per year in hemodialysis (95% CI -42 to 240) and with 288 mm³ per year in peritoneal dialysis (95% CI 57 to 519). As can be seen in Table 2, peritoneal dialysis was not significantly associated with higher CAC progression than hemodialysis in both crude and adjusted analyses with Tobit mixed models (crude difference 189 mm³ per year; 95% CI -81 to 459; $p = 0.17$; and fully adjusted difference 106 mm³ per year; 95% CI -140 to 352; $p = 0.40$).

Calcification Biomarkers

At inclusion, we measured calcification biomarkers in the longitudinal cohort ($n = 57$). Dp-ucMGP levels were median 1,689 (IQR 1,304–3,470) pmol/L in hemodialysis, and 1,548 (IQR 900–1,822) pmol/L in peritoneal dialysis. Fetuin-A levels were mean 0.20 ± 0.06 g/L in hemodialysis and 0.21 ± 0.08 g/L in peritoneal dialysis. Osteoprotegerin were mean 3.2 ± 1.4 μ g/L in hemodialysis and 3.3 ± 1.2 μ g/L in peritoneal dialysis. In univariate analyses, peritoneal dialysis was not associated with differences in dp-ucMGP, fetuin-A, or osteoprotegerin levels (online suppl. Table S2). When adjusted for age, sex, diabetes mellitus, dialysis vintage, vitamin K antagonist use, and presence of residual urine production, peritoneal dialysis was associated with 0.83 μ g/L higher osteoprotegerin lev-

els than hemodialysis (95% CI 0.13 to 1.52; $p = 0.02$), but not with differences in dp-ucMGP or fetuin-A. Osteoprotegerin correlated with Δ CAC SQRV (Pearson's correlation coefficient 0.32, $p = 0.05$), while dp-ucMGP and fetuin-A did not correlate with Δ CAC SQRV (Pearson's correlation coefficients 0.23, $p = 0.13$; and -0.01, $p = 0.93$).

Discussion

Our study investigated whether vascular calcification develops less in peritoneal dialysis than in hemodialysis, cross-sectionally and longitudinally. In a large cross-sectional cohort, we found that patients treated with peritoneal dialysis do not have less CAC than patients treated with hemodialysis. In the longitudinal cohort, we found that patients on peritoneal dialysis do not have less CAC progression than patients on hemodialysis. Altogether, this indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.

Few studies have compared vascular calcification between hemodialysis and peritoneal dialysis, that is, 3 cross-sectional studies and one longitudinal study. An American cross-sectional study found more frequent CAC in pediatric patients on hemodialysis (9/21 patients) than on peritoneal dialysis (2/17 patients) [11]. An Albanian cross-sectional study found more frequent cardiac valve calcification in adult patients on hemodialysis (24/34 patients) than on peritoneal dialysis (10/30 patients) [12]. A Korean cross-sectional study did not find a significant difference in CAC score between patients on hemodialysis ($n = 31$, median score 30) and those on peritoneal dialysis ($n = 15$, median score 16) [13]. Finally, a Taiwanese study did not find significant differences in

CAC score or one-year CAC progression between patients on hemodialysis ($n = 18$, median score increased from 110 to 175) and patients on peritoneal dialysis ($n = 15$, median score increased from 3 to 76) [14, 24]. However, all of these studies had imbalances in age, dialysis vintage, or comorbidities between groups, which were not adjusted for statistically. In addition, the longitudinal study analyzed CAC progression as percentage change, which yields biased results because of the skewed distribution of CAC scores with excessive zeros [5].

The problematic distribution of CAC scores precludes many strategies commonly used to analyze changes. This is also why a standard method to analyze CAC progression is lacking. We therefore chose to analyze CAC progression with 2 approaches that are valid from a statistical viewpoint: as Δ CAC SQRV with linear mixed models and with Tobit mixed models. Our data showed a significant effect with the former approach that appears larger than that with the latter approach. In fact, if we maintained the definition of CAC progression $\geq 2.5 \Delta$ CAC SQRV by Hokanson et al. [21], there would be 6 out of 34 patients on hemodialysis with progression and 9 out of 23 patients on peritoneal dialysis with progression, implying a number needed to harm of 4.7 patients to make one more patient progress in CAC on peritoneal dialysis than on hemodialysis. However, this larger effect may be due to modest right-skewness of Δ CAC SQRV, despite the square root transformation. On the other hand, this larger effect may be because Tobit mixed models could not be adjusted for CAC score at inclusion. Nevertheless, the estimates from both analyses are in the same direction, which support our conclusion that peritoneal dialysis is not associated with *less* CAC progression than hemodialysis.

There could be some explanations for our unexpected finding that peritoneal dialysis is not associated with less CAC or CAC progression. On the one hand, patients on peritoneal dialysis may have had a greater time-averaged exposure to phosphate than patients on hemodialysis. After all, time-averaged phosphate exposure in hemodialysis is lower than suggested by pre-dialysis phosphate levels because of the sawtooth pattern in hemodialysis [25]. On the other hand, there could have been differences in calcium balance. Patients on hemodialysis might have had a positive calcium balance with the default dialysate calcium concentration of 1.50 mmol/L based on kinetic modeling studies [26], but it is unknown whether patients on peritoneal dialysis also had a positive calcium balance with a default dialysate calcium concentration of 1.25 mmol/L, as this also depends on ultrafiltration [27]. This would require detailed calcium balance studies.

Our findings regarding the 3 calcification biomarkers do not allow firm conclusions and need further exploration. First, we found that osteoprotegerin was associated with progression of CAC, in accordance with previous studies [28, 29]. Nevertheless, osteoprotegerin should theoretically protect against vascular calcification by preventing the receptor activator of nuclear factor- κ B ligand from binding to the RANK receptor [30]. Whether our finding indicates a compensatory response requires additional study. Second, we did not find a significant association between CAC progression and dp-ucMGP. Dp-ucMGP is an inverse marker of calcification inhibition potential, as its active form inhibits vascular calcification after carboxylation by vitamin K [31]. It is possible that larger samples are needed to study the relationship between CAC progression and dp-ucMGP. Third, we did not find any relationship between fetuin-A and CAC progression. Fetuin-A is a hepatic protein that forms soluble complexes with calcium and phosphate (calciprotein particles [CPPs]) and thus prevents calcification [32]. The reason we did not find a relationship with CAC progression lies probably in these CPPs: an ordinary fetuin-A measurement includes the CPP-bound fetuin-A, which is the fetuin-A fraction that has already been used up. Future studies should measure the non-CPP-bound fraction of fetuin-A after an extra centrifugation step [33], or should measure CPPs directly [34].

Our results should be interpreted within certain limitations. The size of our longitudinal cohort was small and patients on peritoneal dialysis had a limited follow-up duration. Larger studies are necessary to investigate whether peritoneal dialysis may be associated with more CAC than hemodialysis and to investigate the relationship between calcification biomarkers and CAC progression. Also, our study was non-randomized, although randomization to dialysis modalities has proven infeasible in earlier studies [9].

Our study has several strengths as well. This study is the largest so far to compare vascular calcification between hemodialysis and peritoneal dialysis, combining a large cross-sectional cohort with follow-up data on progression of CAC. Also, we accounted for the skewness and zero-inflation of CAC scores by using 2 statistically valid approaches that enabled essential adjustment for potential confounders. Moreover, the patients on hemodialysis and peritoneal dialysis in our study were relatively comparable, as this study only included patients eligible for transplantation.

In conclusion, peritoneal dialysis is not associated with less CAC nor less CAC progression than hemodialysis. This indicates that vascular calcification does not develop

less in peritoneal dialysis. Further studies should investigate whether vascular calcification develops even more in peritoneal dialysis.

Acknowledgments

We thank the following centers for recruiting patients for the NOCTx study: Dialysecentrum Groningen, Groningen, the Netherlands; Diapriva Dialysecentrum and VU Medisch Centrum, Amsterdam, the Netherlands; Meander Medisch Centrum, Amersfoort, the Netherlands; Rijnstate Ziekenhuis, Arnhem, the Netherlands; Sint Antoniusziekenhuis, Nieuwegein, the Netherlands; Stichting Dianet Dialysecentra and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands. We thank Dr. L.J. Schurgers for providing the dp-ucMGP measurements, and Dr. I. Hoefler for the fetuin-A and osteoprotegerin measurements.

Ethics Statement

All subjects provided written informed consent. The study protocol has been approved by the Medical Ethics Committee of the University Medical Center Utrecht and the study was conducted according to the Declaration of Helsinki.

References

- 1 United States Renal Data System: US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis* 2016;67:SA1–SA8, S1–S434.
- 2 Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 2000;342:1478–1483.
- 3 Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. *Clin J Am Soc Nephrol* 2007;2:1241–1248.
- 4 London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 2003;18:1731–1740.
- 5 Jansz TT, Verhaar MC, London GM, van Jaarsveld BC: Is progression of coronary artery calcification influenced by modality of renal replacement therapy? A systematic review. *Clin Kidney J* 2018;11:353–361.
- 6 Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. *Nat Rev Nephrol* 2017;13:27–38.
- 7 Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol* 2002;39:695–701.
- 8 Noordzij M, Korevaar JC, Bos WJ, Boeschoten EW, Dekker FW, Bossuyt PM, Krediet RT: Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. *Nephrol Dial Transplant* 2006;21:2513–2520.
- 9 Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT; NECOSAD Study Group: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. *Kidney Int* 2003;64:2222–2228.
- 10 Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhavne N, Bragg-Gresham J, Balkrishnan R, Dietrich X, Eckard A, Eggers PW, Gaipov A, Gillen D, Gipson D, Hailpern SM, Hall YN, Han Y, He K, Herman W, Heung M, Hirsh RA, Hutton D, Jacobsen SJ, Jin Y, Kalantar-Zadeh K, Kapke A, Kovesdy CP, Lavalley D, Leslie J, McCullough K, Modi Z, Molnar MZ, Montez-Rath M, Moradi H, Morgenstern H, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O'Hare AM, Obi Y, Park C, Pearson J, Pisoni R, Potukuchi PK, Rao P, Repeck K, Rhee CM, Schragger J, Schaubel DE, Selewski DT, Shaw SF, Shi JM, Shieu M, Sim JJ, Soohoo M, Steffick D, Streja E, Sumida K, Tamura MK, Tilea A, Tong L, Wang D, Wang M, Woodside KJ, Xin X, Yin M, You AS, Zhou H, Shahinian V: US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2018;71:A7.
- 11 Srivaths P, Krishnamurthy R, Brunner L, Logan B, Bennett M, Ma Q, VanDeVoorde R, Goldstein SL: Cardiac calcifications are more prevalent in children receiving hemodialysis than peritoneal dialysis. *Clin Nephrol* 2014;81:231–237.
- 12 Rroji M, Seferi S, Cafka M, Petrela E, Likaj E, Barbullushi M, Thereska N, Spasovski G: Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients? *Int Urol Nephrol* 2014;46:175–182.
- 13 Kim CD, Cho JH, Choi HJ, Jang MH, Kwon HM, Kim JC, Park SH, Lee JM, Cho DK, Kim YL: Coronary-artery calcium scores using electron beam CT in patients with chronic renal failure. *J Korean Med Sci* 2005;20:994–999.

Disclosure Statement

The authors have no conflicts of interest to declare.

Funding Source

T.T.J. is supported financially by a grant from the Wellerdieck de Goede foundation with mediation of the Friends of UMC Utrecht foundation. The NOCTx study is supported by unrestricted grants from Amgen, Baxter, Fresenius Medical Care, Novartis, Roche, and Shire Pharmaceuticals. The funders had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.

Authors Contribution

T.T.J., P.A.J., T.H., M.C.V., and B.C.V. contributed to the conception and design of this study. T.T.J., M.C.V., and B.C.V. contributed to the analysis and interpretation of the data. T.T.J. and B.C.V. drafted the manuscript. Each author contributed important intellectual content during manuscript drafting or revision and has approved of the final version of the manuscript.

- 14 Lee CM, Chen PW, Leung TK, Wang HJ, Kung CH, Lin YH, Hsiao WT, Chen YY: Comparison of coronary artery calcification in peritoneal and hemodialysis patients. *J Exp Clin Med* 2011;3:89–92.
- 15 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2009;113:S1–S130.
- 16 Sabour S, Atsma F, Rutten A, Grobbee DE, Mali W, Prokop M, Bots ML: Multi-Detector-Row Computed Tomography (MDCT) had excellent reproducibility of coronary calcium measurements. *J Clin Epidemiol* 2008;61:572–579.
- 17 Jansz TT, Neradova A, van Ballegooijen AJ, Verhaar MC, Vervloet MG, Schurgers LJ, van Jaarsveld BC: The role of kidney transplantation and phosphate binder use in vitamin K status. *PLoS One* 2018;13:e0203157.
- 18 Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Pottel H, Cavalier E: Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. *BMC Nephrol* 2014;15:145.
- 19 Twisk J, Rijmen F: Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. *J Clin Epidemiol* 2009;62:953–958.
- 20 Spriensma AS, Eelchout I, de Boer MR, Luime JJ, de Jong PH, Bahcecitapar MK, Heymans MW, Twisk JW: Analysing outcome variables with floor effects due to censoring: a simulation study with longitudinal trial data. *Epidemiol Biostat Pu* 2018;15:e12850.
- 21 Hokanson JE, MacKenzie T, Kinney G, Snell-Bergeon JK, Dabelea D, Ehrlich J, Eckel RH, Rewers M: Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. *AJR Am J Roentgenol* 2004;182:1327–1332.
- 22 Malluche HH, Blomquist G, Monier-Faugere MC, Cantor TL, Davenport DL: High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis. *J Am Soc Nephrol* 2015;26:2534–2544.
- 23 Vervloet M, Cozzolino M: Vascular calcification in chronic kidney disease: different bricks in the wall? *Kidney Int* 2017;91:808–817.
- 24 Lee H, Yoon YE, Kim YJ, Kim HL, Lee SP, Kim HK, Cho GY, Zo JH, Sohn DW: Presence and extent of coronary calcified plaque evaluated by coronary computed tomographic angiography are independent predictors of ischemic stroke in patients with suspected coronary artery disease. *Int J Cardiovasc Imaging* 2015;31:1469–1478.
- 25 Evenepoel P, Meijers BK, Bammens B, Viaene L, Claes K, Sprangers B, Naesens M, Hoekstra T, Schlieper G, Vanderschueren D, Kuypers D: Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. *Nephrol Dial Transplant* 2016;31:1508–1514.
- 26 Gotch FA, Kotanko P, Thijssen S, Levin NW: The KDIGO guideline for dialysate calcium will result in an increased incidence of calcium accumulation in hemodialysis patients. *Kidney Int* 2010;78:343–350.
- 27 Simonsen O, Venturoli D, Wieslander A, Carlsson O, Rippe B: Mass transfer of calcium across the peritoneum at three different peritoneal dialysis fluid Ca²⁺ and glucose concentrations. *Kidney Int* 2003;64:208–215.
- 28 Avila M, Mora C, Prado MDC, Zavala M, Paniagua R; Mexican Collaborative Group: Osteoprotegerin is the strongest predictor for progression of arterial calcification in peritoneal dialysis patients. *Am J Nephrol* 2017;46:39–46.
- 29 Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A: Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. *Clin J Am Soc Nephrol* 2012;7:965–973.
- 30 Hofbauer LC, Schoppet M: Osteoprotegerin: a link between osteoporosis and arterial calcification? *Lancet* 2001;358:257–259.
- 31 Schurgers LJ, Uitto J, Reutelingsperger CP: Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. *Trends Mol Med* 2013;19:217–226.
- 32 Price PA, Lim JE: The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. *J Biol Chem* 2003;278:22144–22152.
- 33 Kuro-o M: Calciprotein particle (CPP): a true culprit of phosphorus woes? *Nefrologia* 2014;34:1–4.
- 34 Miura Y, Iwazu Y, Shiizaki K, Akimoto T, Kotani K, Kurabayashi M, Kurosu H, Kuro-O M: Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease. *Sci Rep* 2018;8:1256.